Atossa Therapeutics (NASDAQ:ATOS - Get Free Report)'s stock had its "buy" rating reaffirmed by research analysts at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $7.00 price target on the stock. HC Wainwright also issued estimates for Atossa Therapeutics' Q1 2025 earnings at ($0.05) EPS, Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.07) EPS, Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.25) EPS, FY2026 earnings at ($0.30) EPS, FY2028 earnings at ($0.22) EPS and FY2029 earnings at ($0.18) EPS.
Separately, Ascendiant Capital Markets lifted their target price on shares of Atossa Therapeutics from $6.50 to $7.00 and gave the stock a "buy" rating in a research report on Monday, December 9th.
Read Our Latest Stock Report on ATOS
Atossa Therapeutics Price Performance
ATOS stock traded down $0.00 during mid-day trading on Wednesday, hitting $0.70. 434,447 shares of the stock were exchanged, compared to its average volume of 984,925. The business has a fifty day moving average price of $0.79 and a 200 day moving average price of $1.10. Atossa Therapeutics has a 12 month low of $0.66 and a 12 month high of $2.31. The stock has a market capitalization of $89.93 million, a price-to-earnings ratio of -3.16 and a beta of 1.20.
Atossa Therapeutics (NASDAQ:ATOS - Get Free Report) last released its earnings results on Tuesday, March 25th. The company reported ($0.05) earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $0.01. As a group, equities analysts forecast that Atossa Therapeutics will post -0.22 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in the company. Gallagher Capital Advisors LLC bought a new stake in Atossa Therapeutics in the 4th quarter worth $25,000. Millennium Management LLC bought a new stake in shares of Atossa Therapeutics in the fourth quarter worth about $28,000. Intech Investment Management LLC purchased a new position in Atossa Therapeutics during the 3rd quarter valued at about $29,000. Two Sigma Advisers LP raised its position in Atossa Therapeutics by 214.1% during the 4th quarter. Two Sigma Advisers LP now owns 42,400 shares of the company's stock valued at $40,000 after purchasing an additional 28,900 shares during the last quarter. Finally, Wells Fargo & Company MN lifted its holdings in Atossa Therapeutics by 30.7% in the 4th quarter. Wells Fargo & Company MN now owns 71,720 shares of the company's stock worth $68,000 after buying an additional 16,853 shares during the period. 12.74% of the stock is owned by hedge funds and other institutional investors.
About Atossa Therapeutics
(
Get Free Report)
Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.
See Also
Before you consider Atossa Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atossa Therapeutics wasn't on the list.
While Atossa Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
